



## Correction to: Elagolix: First Global Approval

Yvette N. Lamb<sup>1</sup>

Published online: 15 November 2018  
© Springer Nature 2018

**Correction to: Drugs (2018) 78(14):1501–1508**  
<https://doi.org/10.1007/s40265-018-0977-4>

The article Elagolix: First Global Approval, written by Yvette N. Lamb, was originally published Online First without open access. After publication in volume 78, issue 14, pages 1501–1508 AbbVie Inc., requested that the article be Open Choice to make the article an open access publication. Post-publication open access was funded by AbbVie Inc. The article is forthwith distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits any noncommercial use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to

the Creative Commons license and indicate if changes were made.

The original article has been corrected.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits any noncommercial use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

---

The original article can be found online at <https://doi.org/10.1007/s40265-018-0977-4>.

---

✉ Yvette N. Lamb  
[dru@adis.com](mailto:dru@adis.com)

<sup>1</sup> Springer, Private Bag 65901, Mairangi Bay, 0754 Auckland, New Zealand